Evolving Roles of KRAS Inhibitors in CRC by HMP Global

The Role of Tumor Mutation Burden Featuring Dr Morris by HMP Global

Dr Morris Discusses Emerging Targeted Therapies in mCRC by HMP Global

Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC.

Carla Casulo, MD, Associate Professor, Wilmot Cancer Institute, University of Rochester, New York, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed follicular lymphoma (FL).

Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II by HMP Global

Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer by HMP Global

Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC by HMP Global

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.